Cargando…
Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections
BACKGROUND/AIMS: Although multidrug resistance (MDR) among extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) poses significant therapeutic challenges, little is known regarding the risk factors and epidemiology of community-onset MDR-ESBL-EC infections. We performed this study to in...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214718/ https://www.ncbi.nlm.nih.gov/pubmed/27093979 http://dx.doi.org/10.3904/kjim.2015.113 |
_version_ | 1782491655511736320 |
---|---|
author | Park, So Yeon Kang, Cheol-In Wi, Yu Mi Chung, Doo Ryeon Peck, Kyong Ran Lee, Nam-Yong Song, Jae-Hoon |
author_facet | Park, So Yeon Kang, Cheol-In Wi, Yu Mi Chung, Doo Ryeon Peck, Kyong Ran Lee, Nam-Yong Song, Jae-Hoon |
author_sort | Park, So Yeon |
collection | PubMed |
description | BACKGROUND/AIMS: Although multidrug resistance (MDR) among extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) poses significant therapeutic challenges, little is known regarding the risk factors and epidemiology of community-onset MDR-ESBL-EC infections. We performed this study to investigate risk factors and the molecular epidemiology of community-onset MDR-ESBL-EC infections. METHODS: We conducted a case-control-control study of community-onset infections. MDR-ESBL-EC was defined as ESBL-EC that demonstrated in vitro resistance to trimethoprim-sulfamethoxazole, fluoroquinolones (FQs), and gentamicin. Patients with MDR-ESBL-EC infections were designated as case patients. A control group I (CG I) patient was defined as a person whose clinical sample yielded ESBL-EC that did not meet the criteria for MDR. A control group II (CG II) patient was defined as a patient with a non-ESBL-EC infection. RESULTS: Of 108 patients with ESBL-EC infections, 30 cases (27.8%) were due to MDR-ESBL-EC. Compared with CG I, prior use of FQs (odds ratio [OR], 3.16; 95% confidence interval [CI], 1.11 to 8.98) and immunosuppressant use (OR, 10.47; 95% CI, 1.07 to 102.57) were significantly associated with MDR-ESBL-EC. Compared with CG II, prior use of FQs (OR, 15.53; 95% CI, 2.86 to 84.27) and healthcare-associated infection (OR, 5.98; 95% CI, 2.26 to 15.86) were significantly associated with MDR-ESBL-EC. CTX-M-15 was the most common in MDR-ESBL-EC infections (59.1% [13/22]), while CTX-M-14 was the most common in non-MDR-ESBL-EC infections (41.6% [32/77]). CTX-M-15 was significantly associated with MDR-ESBL-EC (59.1% vs. 32.5%, p = 0.028). Pulsed-field gel electrophoresis showed clonal diversity of MDR-ESBL-EC isolates. CONCLUSIONS: The emergence of strains of MDR-ESBL-EC in the community poses an important new public health threat. More information on the emergence and transmission of these strains will be necessary in order to prevent their spread. |
format | Online Article Text |
id | pubmed-5214718 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Korean Association of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-52147182017-01-11 Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections Park, So Yeon Kang, Cheol-In Wi, Yu Mi Chung, Doo Ryeon Peck, Kyong Ran Lee, Nam-Yong Song, Jae-Hoon Korean J Intern Med Original Article BACKGROUND/AIMS: Although multidrug resistance (MDR) among extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) poses significant therapeutic challenges, little is known regarding the risk factors and epidemiology of community-onset MDR-ESBL-EC infections. We performed this study to investigate risk factors and the molecular epidemiology of community-onset MDR-ESBL-EC infections. METHODS: We conducted a case-control-control study of community-onset infections. MDR-ESBL-EC was defined as ESBL-EC that demonstrated in vitro resistance to trimethoprim-sulfamethoxazole, fluoroquinolones (FQs), and gentamicin. Patients with MDR-ESBL-EC infections were designated as case patients. A control group I (CG I) patient was defined as a person whose clinical sample yielded ESBL-EC that did not meet the criteria for MDR. A control group II (CG II) patient was defined as a patient with a non-ESBL-EC infection. RESULTS: Of 108 patients with ESBL-EC infections, 30 cases (27.8%) were due to MDR-ESBL-EC. Compared with CG I, prior use of FQs (odds ratio [OR], 3.16; 95% confidence interval [CI], 1.11 to 8.98) and immunosuppressant use (OR, 10.47; 95% CI, 1.07 to 102.57) were significantly associated with MDR-ESBL-EC. Compared with CG II, prior use of FQs (OR, 15.53; 95% CI, 2.86 to 84.27) and healthcare-associated infection (OR, 5.98; 95% CI, 2.26 to 15.86) were significantly associated with MDR-ESBL-EC. CTX-M-15 was the most common in MDR-ESBL-EC infections (59.1% [13/22]), while CTX-M-14 was the most common in non-MDR-ESBL-EC infections (41.6% [32/77]). CTX-M-15 was significantly associated with MDR-ESBL-EC (59.1% vs. 32.5%, p = 0.028). Pulsed-field gel electrophoresis showed clonal diversity of MDR-ESBL-EC isolates. CONCLUSIONS: The emergence of strains of MDR-ESBL-EC in the community poses an important new public health threat. More information on the emergence and transmission of these strains will be necessary in order to prevent their spread. The Korean Association of Internal Medicine 2017-01 2016-04-20 /pmc/articles/PMC5214718/ /pubmed/27093979 http://dx.doi.org/10.3904/kjim.2015.113 Text en Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Park, So Yeon Kang, Cheol-In Wi, Yu Mi Chung, Doo Ryeon Peck, Kyong Ran Lee, Nam-Yong Song, Jae-Hoon Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections |
title | Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections |
title_full | Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections |
title_fullStr | Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections |
title_full_unstemmed | Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections |
title_short | Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections |
title_sort | risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing escherichia coli infections |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214718/ https://www.ncbi.nlm.nih.gov/pubmed/27093979 http://dx.doi.org/10.3904/kjim.2015.113 |
work_keys_str_mv | AT parksoyeon riskfactorsandmolecularepidemiologyofcommunityonsetmultidrugresistanceextendedspectrumblactamaseproducingescherichiacoliinfections AT kangcheolin riskfactorsandmolecularepidemiologyofcommunityonsetmultidrugresistanceextendedspectrumblactamaseproducingescherichiacoliinfections AT wiyumi riskfactorsandmolecularepidemiologyofcommunityonsetmultidrugresistanceextendedspectrumblactamaseproducingescherichiacoliinfections AT chungdooryeon riskfactorsandmolecularepidemiologyofcommunityonsetmultidrugresistanceextendedspectrumblactamaseproducingescherichiacoliinfections AT peckkyongran riskfactorsandmolecularepidemiologyofcommunityonsetmultidrugresistanceextendedspectrumblactamaseproducingescherichiacoliinfections AT leenamyong riskfactorsandmolecularepidemiologyofcommunityonsetmultidrugresistanceextendedspectrumblactamaseproducingescherichiacoliinfections AT songjaehoon riskfactorsandmolecularepidemiologyofcommunityonsetmultidrugresistanceextendedspectrumblactamaseproducingescherichiacoliinfections |